For me this is a long-term trade. We need to see the contract manufacturing expand and for the trials to progress more. Once the drug trials reach the 3rd stage I don't see why this stock shouldn't be valued at the similar price to sales ratio as other (OPK included) biotechs. One thing that I feel is missed with this company is that market since the lipids will replace the hardcore solvents, BUT why can't this delivery method of drugs be wide spread. I see nurses in the hospital asking a patient if they want a drug intravenously, want it in a pill or if they want it administered topically on the skin.
IMO, this company is a sleeping giant if it is able to do what it aims to do. One of those stocks that deliver $2,000 for every $1 invested type bets.
I have no idea where some of my posts are ending up. Fact is, there has been a lot of time (almost 2 years) devoted by Dr. Frost and he is now pulling triggers. Long term is not the play here. The word is out and if there's speculation (which there is now) this price is going to be one of the best Christmas present you've ever received.
Part of the deal with OPK was that they also got their hands on a form of Propofol. Annual sales of $500M. A clear formula was part of the deal here and the delivery method maybe something that helps this drug with a lower dosage?
OPK also has their sites on the eye industry, with drugs. I wonder if our delivery method would aid in this field? I'm trying to find the link that has to be there now after 1.5 years of being in bed with OPK.